Table 1.
Baseline demographic and clinical characteristics of the studied groups.
| Active RA (n = 81) | Remission RA (n = 39) | Control | p-Value | |
|---|---|---|---|---|
| Age | 54.52 ± 7.31 | 55.08 ± 6.86 | 53.08 ± 7.45 | 0.436 |
| Female% | 55 (67.9%) | 27 (69.2%) | 25 (62.5%) | 0.788 |
| Current smoker | 12 (14.8%) | 7 (17.9%) | 9 (22.5%) | 0.584 |
| Systolic blood pressure (mm Hg) | 129.63 ± 9.87 | 132.18 ± 10.18 | 128.38 ± 6.64 | 0.176 |
| Diastolic blood pressure (mm Hg) | 85.17 ± 6.94 | 85.77 ± 7.39 | 83.38 ± 5.24 | 0.240 |
| Heart rate (beats/min) | 77.75 ± 9.05 | 77.18 ± 8.86 | 76.25 ± 8.75 | 0.684 |
| RA disease characteristics | ||||
| Disease duration (years) | 8.47 ± 3.83 | 7.92 ± 3.47 | 0.453 | |
| SDAI score | 11.18 ± 7.59 | 2.12 ± 0.46 | <0.001 | |
| DAS28 | 3.42 ± 0.80 | 1.98 ± 0.25 | <0.001 | |
| Laboratory | ||||
| Total serum cholesterol (mg/dl) | 195.68 ± 28.58 | 200.26 ± 32.75 | 197.58 ± 31.34 | 0.739 |
| RF positive | 55 (67.9%) | 19 (48.7%) | <0.001 | |
| Anti CCP positive | 52 (64.1%) | 15 (38.4%) | <0.001 | |
| Serum creatinine (mg/dl) | 1.13 ± 0.21 | 1.11 ± 0.29 | 1.17 ± 0.20 | 0.523 |
| CRP (mg/L) | 12.31 ± 5.70 | 3.21 ± 1.26a | 0.59 ± 0.31a | <0.001 for active vs control and active vs remission and 0.033 for remission vs control |
| ESR (mm/hour) | 60.30 ± 8.89 | 33.85 ± 5.90a | 8.53 ± 2.63ab | <0.001 for active vs control and active vs remission and 0.042 for remission vs control |
| Medications | ||||
| DMARDS% | 60 (74%) | 20 (51.2%) | <0.001 | |
| TNFI% | 17 (20.9%) | 6 (15.3%) | <0.001 | |
| Methotrexate% | 28 (34.5%) | 13 (33.3%) | <0.001 | |
| Corticosteroids% | 35 (43.2%) | 14 (35.8%) | <0.001 | |
All data are represented as mean ± SD and number (percent).
a: significant with active group, b: significant with Remission group.
RA, rheumatoid arthritis; SDAI, Simplified Disease Activity Index; DAS28, Disease Activity Score in 28 Joints; RF, rheumatoid factor; Anti-CCP, anti-cyclic citrullinated peptide; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; DMARDs, disease modifying antirheumatic drugs; TNFi, tumour necrosis factor inhibitor.